3Q23 & 9M23 Performance Overview

RETAIL (PHARMACY) BUSINESS OPERATING PERFORMANCE OVERVIEW RETAIL (PHARMACY) KEY DRIVERS The y-o-y increase in revenues and EBITDA reflects the expansion of the pharmacy chain and franchise stores, along with overall economic growth in Georgia, partially subdued by: О о The decrease in product prices due to GEL's appreciation against foreign currencies; The negative impact of the External Reference Pricing model; The decrease in wholesale revenues due to the impact of new government regulations, which led to the closure of certain partner pharmacies in 2023, which our pharmacy business held wholesale distribution agreements with. The business added 26 pharmacies and 3 franchise stores over the last 12 months. Georgia Capital PLC | 1. Excluding IFRS 16. GEL MILLION +5.2% REVENUE DEVELOPMENT 190 200 581 +3.3% 600 18 +15.6% EBITDA¹ DEVELOPMENT 21 57 57 GEORGIA CAPITAL +8.5% 61 3Q22 3Q23 9M22 9M23 3Q22 3Q23 9M22 9M23 KEY OPERATING HIGHLIGHTS 3Q22 VS. ■3Q23 Change y-o-y 9M22 VS. 9M23 Change y-o-y # of pharmacies & franchise stores 378 407 +7.7% 378 407 +7.7% Same store revenue growth -3.1% 3.5% +6.6ppts 2.2% 1.0% -1.2ppts # of bills issued (mln) 7.5 7.6 +1.1% 22.5 23.1 +2.5% Average bill size 18.8 20.0 +6.7% 19.1 19.5 +2.5% 52

View entire presentation